Generative Art Platform Fxhash Secures $5M in Seed Funding Round Led by 1kx
The Seed Round Fxhash, the groundbreaking generative art platform and marketplace, has successfully closed an oversubscribed $5 million seed fundraising round. Spearheading this investment initiative was 1kx, an early-stage crypto-focused venture capital firm renowned for its strategic ecosystem growth investments. Founded in 2021, Fxhash has emerged as the...
Cure Parkinson’s Fundraiser On FX Hash Started Today
Today, the Cure Parkinson’s fundraiser started with a specially commissioned selection of generative NFTs minted on the Tezos-based NFT platform fx(hash).
This is part of the fourth edition of Cure3, the critically acclaimed selling exhibition devised to raise awareness and funds for curative Parkinson’s research.
By: Lee Evans
12 January 2023
Disclaimer
Not Financial Advice: No content on this website constitutes investment, financial, legal, or tax advice. Users should not construe any such information as a recommendation to buy, sell, or hold any investment or security or to pursue any particular investment strategy.
Today, the Cure Parkinson’s fundraiser started with a specially commissioned selection of generative NFTs minted on Tezos-based NFT platform fx(hash).
This is part of the fourth edition of Cure3, the critically acclaimed selling exhibition devised to raise awareness and funds for curative Parkinson’s research.
“We’re super excited about the opportunity to support Parkinson’s Research while helping generative art reach new audiences & collectors, and we hope you’ll join us for this special fundraising event both online and in person during the public viewing.” – Fx(hash)
Parkinson’s disease
Parkinson’s disease is a long-term degenerative disorder of the central nervous system that mainly affects the motor system.
The symptoms usually emerge slowly, and as the disease worsens, non-motor symptoms become more common.
Parkinson’s is affecting over 145,000 people in the UK alone and 10 million people worldwide.
It is predicted that 1 person in 37 will receive a diagnosis of Parkinson’s in their lifetime.
The cause of Parkinson’s is unknown, and thus a cure is hard to find.
There are a lot of areas of research to find the cause and a cure for Parkinson’s though.
One subject of focus is Alpha-synuclein.
Alpha-synuclein is a protein that is extremely abundant in our brains, making up around 1% of all the proteins floating around in each neuron (one of the main types of cell in the brain).
Five genetic mutations in the alpha-synuclein gene have been identified as an associated increased risk of Parkinson’s – these account for 10-20% of Parkinson’s cases.
An area of research Cure Parkinson’s is involved in is that of the medicine, ambroxol, which has shown to improve the waste clearance from cells, including the mis-folded alpha-synuclein.
For more info about this subject, visit the website of Cure Parkinson’s.
Cure Parkinson’s and Cure3
Cure Parkinson’s funds research that slows, stops, or reverses Parkinson’s.
As a call to action, art and science unite with Cure3 (Cure Cubed), which is an acclaimed contemporary art fundraising exhibition.
Cure3 was established in 2017 and is now launching its 4th edition, devised and curated by Artwise in partnership with Bonhams to raise awareness and funds for Cure Parkinson’s.
The unique concept for Cure3 centers around each artist being given a bespoke Perspex cube measuring just 20cm3 as a compact space to interact with in any way to create original artworks on or within.
The resultant highly sought-after and collectable artworks are exhibited at Bonhams and sold online.
Curated by Foteini Valeonti and Alex Estorick, with the support of fx(hash), the works will be presented alongside the CUBES and SQUARES at Bonhams, London and for sale to raise money and help find a cure for Parkinson’s.
To date, Cure3 has raised over 1 million GBP and worked with an impressive selection of participating artists.
Start of the NFT sales
Mintable projects go live from 18:00 (BST), January 12 on fx(hash).
Fx(hash) will post links to the projects in advance on their Twitter account so interested collectors can find the works via direct link.
So, make sure you check out fx(hash) on their Twitter account which can be found here.
Disclaimer
Not Financial Advice: No content on this website constitutes investment, financial, legal, or tax advice. Users should not construe any such information as a recommendation to buy, sell, or hold any investment or security or to pursue any particular investment strategy.
Complete the submission form, which includes fields for your name, contact information, a short author bio, and the title of your article. Submit your Word document as a word doc file. If you encounter any issues during the submission process, please contact our support team for assistance at [email protected]. We encourage all aspiring contributors to read and understand our submission guidelines and editorial policy before submitting.
Etherlink, the Tezos blockchain’s latest Layer 2 solution, is set to redefine the landscape of decentralized applications (DApps) with its upcoming mainnet launch in March 2024. This EVM-compatible, optimistic rollup distinguishes itself from other external Layer 2 platforms like Arbitrum, Optimism, and Polygon, due to its unique enshrinement within the Tezos blockchain.
Starting on December 6 with an exhibition, panels and performances at the Nautilus Hotel, curatorial platforms, partners and marketplaces from around the world will co-curate contemporary digital art minted on Tezos. Over 50 works will be shown, ranging from historical pieces to contemporary editions sold during the event, with a portion of the proceeds going to the Trevor Project, an American nonprofit organisation raising funds for suicide prevention amongst LGBTQ+ youth.
The Tezos Foundation announces its support for the Vigicard project, the first mobile application improving the monitoring of patients subject to drug allergies. Based on Tezos blockchain technology, the application was co-developed by a team of Europe-renowned allergists from Montpellier University Hospital, and Web3 experts Codinsight.